Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific target and a cytotoxic drug connected via a linker molecule. Several ADCs are developed against different UC surface markers, but the ones at most advanced stages of development include sacituzumab govitecan (IMMU-132), enfortumab vedotin (ASG-22CE/ASG-22ME), ASG-15ME for advanced UC, and oportuzumab monatox (VB4-845) for early UC. Several new targets are identified and utilized for novel or existing ADC testing. The most promising ones include human epidermal growth factor receptor 2 (HER2) and members of the fibroblast growth factor receptor axis (FGF/FGFR). Positive preclinical and early clinical results are reported in many cases, thus the next step involves further improving efficacy and reducing toxicity as well as testing combination strategies with approved agents.
Bladder cancer (Amsterdam, Netherlands). 2018 Jul 30*** epublish ***
Panagiotis J Vlachostergios, Christopher D Jakubowski, Muhammad J Niaz, Aileen Lee, Charlene Thomas, Amy L Hackett, Priyanka Patel, Naureen Rashid, Scott T Tagawa
Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.